Literature DB >> 27258938

Insulin Plays a Permissive Role for the Vasoactive Effect of GIP Regulating Adipose Tissue Metabolism in Humans.

Meena Asmar1, Lene Simonsen1, Ali Asmar1, Jens Juul Holst1, Flemming Dela1, Jens Bülow1.   

Abstract

CONTEXT AND
OBJECTIVE: Glucose-dependent insulinotropic polypeptide (GIP) in combination with hyperinsulinemia increases blood flow and triglyceride (TAG) clearance in subcutaneous (sc) abdominal adipose tissue in lean humans. The present experiments were performed to further investigate the role of insulin for the vasoactive effect of GIP in adipose tissue metabolism and whether the vasodilatory effect of GIP is dependent on C-peptide.
METHODS: Six lean healthy subjects were studied. The sc abdominal adipose tissue metabolism was assessed by Fick's principle during GIP infusion (1.5 pmol/kg/min) in combination with 1) euglycemic-high insulinemic clamp (Eugluc-Hiinsu), raising plasma insulin concentrations to postprandial levels, 2) hyperglycemic-euinsulinemic clamp (Hygluc-Euinsu), and 3) hyperglycemic-hyperinsulinemic clamp, raising plasma insulin concentrations to supraphysiological levels. During the hyperglycemic clamps, endogenous insulin and C-peptide secretion were inhibited by infusion of the somatostatin analogue octreotide.
RESULTS: During GIP infusion, Eugluc-Hiinsu, and hyperglycemic-hyperinsulinemic clamps, sc abdominal adipose tissue blood flow (ATBF) was similar and increased from 2.1 ± 0.2 and 2.2 ± 0.4 ml min(-1) (100 g tissue)(-1) to 7.1 ± 0.6 and 7.6 ± 0.1 ml min(-1) (100 g tissue)(-1), respectively (P < .01). ATBF remained virtually constant (2.7 ± 0.4 ml min(-1) [100 g tissue](-1)) during Hygluc-Euinsu and GIP infusion. In addition, adipose tissue TAG clearance increased significantly (P = .03), whereas free fatty acid output (P = .01), glycerol output (P = .02) and free fatty acid/glycerol release ratio (P = .04) decreased during the Eugluc-Hiinsu clamp compared to Hygluc-Euinsu clamp with GIP.
CONCLUSION: In healthy lean humans, insulin is permissive for GIP to induce an increase in blood flow and TAG clearance in sc abdominal adipose tissue. This effect is independent of C-peptide.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27258938     DOI: 10.1210/jc.2016-1933

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 2.  Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.

Authors:  Thomas Karagiannis; Ioannis Avgerinos; Aris Liakos; Stefano Del Prato; David R Matthews; Apostolos Tsapas; Eleni Bekiari
Journal:  Diabetologia       Date:  2022-05-17       Impact factor: 10.460

3.  Obesity-associated Blunted Subcutaneous Adipose Tissue Blood Flow After Meal Improves After Bariatric Surgery.

Authors:  Teemu Saari; Jukka Koffert; Henri Honka; Saila Kauhanen; Mueez U-Din; Nils Wierup; Andreas Lindqvist; Leif Groop; Kirsi A Virtanen; Pirjo Nuutila
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

4.  Glucagon-like peptide-1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men.

Authors:  Ali Asmar; Meena Asmar; Lene Simonsen; Sten Madsbad; Jens J Holst; Bolette Hartmann; Charlotte M Sorensen; Jens Bülow
Journal:  Physiol Rep       Date:  2017-02

5.  GIP-induced vasodilation in human adipose tissue involves capillary recruitment.

Authors:  Meena Asmar; Ali Asmar; Lene Simonsen; Flemming Dela; Jens Juul Holst; Jens Bülow
Journal:  Endocr Connect       Date:  2019-06       Impact factor: 3.335

Review 6.  Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases.

Authors:  Christoffer Clemmensen; Brian Finan; Timo D Müller; Richard D DiMarchi; Matthias H Tschöp; Susanna M Hofmann
Journal:  Nat Rev Endocrinol       Date:  2019-02       Impact factor: 43.330

Review 7.  Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes.

Authors:  Megan E Capozzi; Richard D DiMarchi; Matthias H Tschöp; Brian Finan; Jonathan E Campbell
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

8.  Oral and intravenous glucose administration elicit opposing microvascular blood flow responses in skeletal muscle of healthy people: role of incretins.

Authors:  Katherine M Roberts-Thomson; Lewan Parker; Andrew C Betik; Glenn D Wadley; Paul A Della Gatta; Thomas H Marwick; Michelle A Keske
Journal:  J Physiol       Date:  2022-02-01       Impact factor: 6.228

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.